Multiple sclerosis: from the University of Siena, new perspectives with a synthetic molecule
A study conducted by the researchers of the University of Siena paves the way to the possibility to develop a new generation of drugs for the treatment of multiple sclerosis, through a synthetic cannabinoid molecule which showed an immunomodulating effect on the cells of patients suffering from this disease. The study has been recently published in the international Journal of Neuroimmunology.
The study tested the pharmacological effects of the synthetized molecule, COR167, in vitro on cells obtained from patients with multiple sclerosis, and showed to be highly selective on the CB2 receptor related to the immune system, having a very strong action even at very low concentration. “Cannabinoids – said Pasquale Annunziata of the University of Siena, first author of the study – are molecules that act on two different receptors, both on the central nervous system (CB1) and on the cells of the immune system (CB2). For years, scientists have been trying to synthetize a molecule that would act on CB2 receptor only, thus avoiding the psychotropic effects due to interactions with the CB1 receptor”.
“The evident scientific impact of the results of our study – said Federico Corelli, study co-author – is that the COR167 molecule has shown to have a very strong action on patient cells, which had never been seen with other CB2-selective agents before. The study opens new perspectives to the future development of new drugs that can act on immune system remodulation and not only on symptomatic treatments, as it has been done so far, and therefore to a potential cure of this disease”.